Apply for Zavesca (Miglustat) Copay Assistance

Zavesca copay assistance means outside financial help that can lower what you pay for Zavesca or generic miglustat. Depending on your insurance, that help may come from a manufacturer copay card, a manufacturer patient assistance program, or a grant from an independent charitable foundation.

QuickRx Specialty Pharmacy does the legwork for you. Our patient navigators check your insurance, look for the options you may qualify for, prepare and submit the applications on your behalf, and keep track of renewals, at no cost to you. Eligible patients may pay $0.*

To get started, call QuickRx at (917) 830-2525 or complete the form on this page.

*Eligibility, benefit amounts and availability are set by each manufacturer or foundation, not by QuickRx. Not all patients qualify, and programs may change or close without notice. QuickRx does not issue copay cards; we apply on your behalf.

Each program sets its own rules. Manufacturer copay cards are generally limited to patients with commercial or private insurance. Federal guidance from the HHS Office of Inspector General explains that manufacturer copay coupons cannot be used by patients whose drug is paid for by federal health care programs such as Medicare or Medicaid.

Patients with Medicare, Medicaid or no insurance may still have options, such as a manufacturer patient assistance program or an independent foundation grant, when one is available for their condition. These usually have their own requirements, such as income and insurance documents.

QuickRx reviews your situation and tells you which options you may qualify for. Call (917) 830-2525 to get started.

Source: HHS Office of Inspector General, Special Advisory Bulletin: Pharmaceutical Manufacturer Copayment Coupons (September 2014).

*Eligibility, benefit amounts and availability are set by each manufacturer or foundation, not by QuickRx. Not all patients qualify, and programs may change or close without notice. QuickRx does not issue copay cards; we apply on your behalf.

No. There is never any cost for QuickRx’s copay assistance services. You will not receive a bill from QuickRx for checking your eligibility, preparing applications, or handling renewals.

*Eligibility, benefit amounts and availability are set by each manufacturer or foundation, not by QuickRx. Not all patients qualify, and programs may change or close without notice. QuickRx does not issue copay cards; we apply on your behalf.

Yes. Generic miglustat 100 mg capsules are available in the United States. Miglustat 100 mg is also sold under the brand names Zavesca and Yargesa.

Which product your plan covers, and what you pay for it, depends on your plan’s formulary. QuickRx can check your benefits before your first fill. Call (917) 830-2525.

Product availability from Lexidrug, Dosage Forms: US (last updated 9/21/2026).

Lexidrug lists these Average Wholesale Prices (AWP) per 100 mg capsule: generic miglustat $321.48, Yargesa $321.48, and Zavesca $225.29. At the labeled Gaucher dose of 3 capsules a day (about 90 capsules a month), that works out to roughly $28,933 a month for generic miglustat or Yargesa and roughly $20,276 a month for Zavesca at AWP.

What you actually pay depends on your plan’s coverage, deductible and coinsurance, and on any assistance you qualify for. Call (917) 830-2525 for a free benefits check.

AWP (Average Wholesale Price) is a published benchmark from Medi-Span, shown in Lexidrug (last updated 9/21/2026, accessed 9/29/2026). It is a reference price only, not a retail price, not a quote and not what you will pay. Monthly figures are simple math (per-capsule AWP x 90 capsules) for illustration only.

Zavesca (miglustat) is an oral capsule in the drug class called glucosylceramide synthase inhibitors. It was first approved by the FDA on July 31, 2003. It works by slowing the body’s production of glucosylceramide, the fatty substance that builds up in type 1 Gaucher disease.

Zavesca and generic miglustat 100 mg are FDA-approved to treat adults with mild to moderate type 1 Gaucher disease for whom enzyme replacement therapy is not a therapeutic option, for example because of allergy, hypersensitivity or poor venous access.

A separate miglustat product, Opfolda 65 mg, is approved only in combination with cipaglucosidase alfa for adults with late-onset Pompe disease who weigh at least 40 kg and are not improving on enzyme replacement therapy.

Drug information from Lexidrug (last updated 9/21/2026). This is not a complete list; ask your doctor or pharmacist about your own situation.

For type 1 Gaucher disease, the labeled adult dose is 100 mg by mouth 3 times a day. Your doctor may lower the dose to 100 mg once or twice a day if you have side effects such as tremor or diarrhea.

Zavesca can be taken with or without food. Taking it between meals may lower the chance of diarrhea. Take your capsules at the same times each day, at regular intervals.

Always follow the dose your own prescriber gives you.

Drug information from Lexidrug (last updated 9/21/2026). This is not a complete list; ask your doctor or pharmacist about your own situation.

Kidney: Miglustat leaves the body unchanged in the urine, so kidney function matters. For type 1 Gaucher disease, the labeled adjustments are: CrCl above 70 mL/minute/1.73 m², no change; CrCl 50 to 70, 100 mg twice daily; CrCl 30 to 50, 100 mg once daily; CrCl below 30, use is not recommended.

Liver: The labeling gives no liver dose adjustments because this has not been studied. Lexidrug notes an adjustment is unlikely to be needed because miglustat is not metabolized by the liver.

Your prescriber will check your kidney function and set your dose. Call (917) 830-2525 with questions.

Drug information from Lexidrug (last updated 9/21/2026). This is not a complete list; ask your doctor or pharmacist about your own situation.

In people treated for type 1 Gaucher disease, side effects reported in more than 10% of patients include diarrhea, weight loss, stomach pain, gas, nausea, vomiting, weakness, dizziness, headache, tremor, leg and muscle cramps, and vision problems.

Side effects reported in 1% to 10% include bloating, loss of appetite, constipation, indigestion, dry mouth, low platelets, heaviness in the arms or legs, memory problems, migraine, tingling, nerve damage in the hands or feet (peripheral neuropathy), unsteady walking, back pain and menstrual changes.

Diarrhea was seen in most patients, often with weight loss in the first 12 months, and decreased over time with continued treatment. Tell your doctor about any side effect that bothers you or does not go away.

Drug information from Lexidrug (last updated 9/21/2026). This is not a complete list; ask your doctor or pharmacist about your own situation.

Peripheral neuropathy: Numbness, tingling or burning in the hands or feet has been reported. Your doctor will check your nerves, and treatment may need to stop if symptoms appear.

Tremor: New or worse tremor usually starts in the first month. It may go away within 1 to 3 months or improve with a lower dose.

Diarrhea: It may improve by cutting back on sugar (sucrose), lactose and other carbohydrates, taking doses between meals, or using anti-diarrhea medicine. Ongoing diarrhea should be checked by your doctor.

Platelets: A mild drop in platelet count (without bleeding) has been seen in patients switched from enzyme replacement therapy. Your doctor may check your blood.

Other: Psychosis has been reported after approval. Get medical help right away for signs of an allergic reaction, such as rash, hives, swelling of the face or throat, or trouble breathing. Zavesca should be prescribed by a doctor experienced in treating Gaucher disease.

Drug information from Lexidrug (last updated 9/21/2026). This is not a complete list; ask your doctor or pharmacist about your own situation.

Lexidrug lists no known significant drug interactions for miglustat. Miglustat is not metabolized by the liver and does not bind to proteins in the blood.

Even so, always tell every doctor and pharmacist about all medicines, supplements and herbal products you take. QuickRx pharmacists can review your medication list; call (917) 830-2525.

Drug information from Lexidrug (last updated 9/21/2026). This is not a complete list; ask your doctor or pharmacist about your own situation.

Monitoring listed in Lexidrug includes: a neurologic exam at the start of treatment and every 6 months (including checks for new or worsening tremor); watching for signs of peripheral neuropathy; tracking diarrhea, gas and stomach pain; tracking weight; checking platelets (mainly if your platelet count was low to begin with); and checking kidney function.

When miglustat is used with cipaglucosidase alfa for Pompe disease, a pregnancy test is also part of monitoring.

Drug information from Lexidrug (last updated 9/21/2026). This is not a complete list; ask your doctor or pharmacist about your own situation.

Based on animal studies, miglustat may harm an unborn baby. Tell your doctor if you are pregnant or planning a pregnancy. When miglustat is used with cipaglucosidase alfa for Pompe disease, it must not be used during pregnancy, and effective birth control is recommended during treatment and for at least 60 days after the last cipaglucosidase alfa dose.

Miglustat is expected to pass into breast milk, and the manufacturer does not recommend breastfeeding during treatment.

Drug information from Lexidrug (last updated 9/21/2026). This is not a complete list; ask your doctor or pharmacist about your own situation.

Gaucher disease is an inherited condition in which a fatty substance called glucosylceramide builds up in the body. MedlinePlus Genetics explains the condition and its types in more detail.

Miglustat competitively and reversibly blocks the enzyme the body uses to make glucosylceramide, which slows how fast it forms. Miglustat is approved for adults with mild to moderate type 1 Gaucher disease when enzyme replacement therapy is not an option.

Drug information from Lexidrug (last updated 9/21/2026). This is not a complete list; ask your doctor or pharmacist about your own situation.

Yes, as an off-label use. Lexidrug lists Niemann-Pick disease type C as an off-label use of miglustat, supported by a randomized controlled trial, an observational study, and consensus clinical management guidelines that recommend it for the neurologic symptoms of the disease.

If your doctor prescribes miglustat for Niemann-Pick disease type C, QuickRx can check your coverage and look for assistance you may qualify for. Call (917) 830-2525.

Off-label means the use is not approved by the FDA for that condition. Insurance coverage and assistance eligibility for off-label use may differ from approved uses.

Drug information from Lexidrug (last updated 9/21/2026). This is not a complete list; ask your doctor or pharmacist about your own situation.

Store Zavesca and generic miglustat capsules at room temperature, 20°C to 25°C (68°F to 77°F). Brief exposure to 15°C to 30°C (59°F to 86°F) is allowed. Opfolda should be kept in its original container at the same temperature and protected from light.

Keep all medicines out of reach of children and pets. Call your QuickRx pharmacist at (917) 830-2525 with storage questions.

Drug information from Lexidrug (last updated 9/21/2026). This is not a complete list; ask your doctor or pharmacist about your own situation.

QuickRx Specialty Pharmacy is a nationwide specialty pharmacy licensed in all 50 states. Our patient navigators handle the time-consuming work of finding assistance options, preparing applications and managing renewals, at no cost to you.

We also offer drug interaction review, prior authorization support and home delivery. Call (917) 830-2525 to get started.

*Eligibility, benefit amounts and availability are set by each manufacturer or foundation, not by QuickRx. Not all patients qualify, and programs may change or close without notice. QuickRx does not issue copay cards; we apply on your behalf.